Vivaldi Biosciences Granted U.S. Patent for Nasal Spray Combination Vaccine for Influenza and COVID-19

FORT COLLINS, Colorado and VIENNA, Austria – September 1, 2026 – Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing nasal spray vaccines for viral respiratory diseases, announced today that the United States Patent and Trademark Office has issued U.S. Patent Number 12,708,663 B2 for its Delta-19 combination vaccine candidate for broad protection against influenza and COVID-19.

Delta-19 uses Vivaldi Biosciences’ Delta NS1 technology platform, which also is the basis for the company’s clinical-stage nasal spray vaccine candidates: DeltaFLU, for broad protection against influenza, and DelNS1 H5N1, for pandemic preparedness and protection against influenza A/H5N1. Delta NS1 vaccine candidates are based on genetically modified influenza virus strains from which the NS1 gene has been deleted (DelNS1) to generate nasal spray vaccines designed to induce a broadly protective immune response without replicating or forming viral progeny.

Most virus attenuation strategies for vaccine development decrease replication efficiency and thus decrease immune responses to the virus. Attenuation by deletion of NS1 increases immunogenicity. DelNS1 vaccine strains rapidly induce the immune signalling protein interferon and broadly cross-reactive antibodies in the upper respiratory tract to confer protection at the point of infection and potentially block virus transmission. Further, DelNS1 vaccines induce cross-reactive systemic antibodies, and T cells that target conserved internal viral proteins and enable a rapid response to re-infection.

Delta-19 expresses the spike protein receptor binding domain (RBD) of SARS-CoV-2, the virus that causes COVID-19, along with influenza virus antigens. Preliminary proof of concept studies in a ferret model demonstrated high neutralizing antibody levels for SARS-CoV-2 and influenza antigens, and protected 100% of the immunized animals against challenge with a wild-type strain of SARS-CoV-2. The vaccine candidate shows excellent growth in Vivaldi’s proprietary Vero cell-based vaccine manufacturing system.

“This patent strengthens both our Delta NS1 vaccine technology platform and our intellectual property portfolio. Delta-19 shows the versatility of our platform and potential for DelNS1 vaccine strains as vectors to deliver antigens from other RNA viruses such as RSV and parainfluenza,” said Douglass B. Given, MD, PhD, CEO and Chairman of Vivaldi Biosciences. “This U.S. patent for our combination influenza-COVID-19 vaccine candidate is our third new U.S. patent in the past ten months, along with patents for our DeltaFLU broadly protective influenza vaccine and high-growth vaccine strain technology, enabling efficient Vero cell-based production of our vaccine candidates.”

About Vivaldi Biosciences

Vivaldi is developing intranasal vaccines intended to elicit superior protection against influenza and other respiratory diseases, based on its DelNS1 technology platform. The company’s clinical-stage vaccine candidates are DeltaFLU, intended for broad protection against influenza A and B strains, and DelNS1 H5N1, a Phase 2-ready vaccine candidate intended to elicit broad protection against highly pathogenic influenza strains with pandemic potential. The company’s Delta-19 combination vaccine candidate for Covid-19 and influenza is in preclinical development. Vivaldi’s Vero cell-based vaccine manufacturing system uses patented advances in production and purification for high yields and excellent purity. Vivaldi is a venture-backed company with operations at the Research Innovation Center at Colorado State University, Fort Collins, Colorado, and in Vienna, Austria. NGN Capital LLC is the company’s lead investor. Learn more at www.vivaldibiosciences.com. Connect with Vivaldi Biosciences on Linkedin and Twitter.

Contact

Doug Given, MD, PhD, MBA

CEO, Vivaldi Biosciences

Tel: +1 415 200 7785

info@vivaldibiosciences.com